Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCTs051260209Phase 2
Key facts
Phase 2, open-label, single-arm trial of tislelizumab, docetaxel, oxaliplatin and tegafur in gastric adenocarcinoma, sponsored by BeOne Medicines. Primary endpoint: Completion rate of preoperative DOS-Tisle therapy. Started Nov 2026; status: recruiting.
Perioperative DOS-Tisle
Three cycles of preoperative tislelizumab plus docetaxel, oxaliplatin, and S-1 followed by curative gastrectomy and postoperative DOS-Tisle therapy.
Adults with histologically confirmed gastric adenocarcinoma that is clinically T3-4 and/or node-positive, without distant metastasis except allowed para-aortic nodal metastasis at station 16a2/b1, and considered resectable with planned R0 surgery. Patients must have good performance status, adequate organ function, adequate oral or enteral nutrition, and no major autoimmune, interstitial lung, transplant, active infection, severe cardiac, pregnancy, or hepatitis B surface antigen positivity exclusions.
Completion rate of preoperative DOS-Tisle therapy
Objective response rate
Pathological response rate
Pathological complete response rate
R0 resection rate
Postoperative DOS-Tisle therapy initiation rate
Postoperative DOS-Tisle therapy completion rate
Overall completion rate of perioperative DOS-Tisle therapy
Incidence of adverse events, including immune-related adverse events
Beyond the preview
Full results, competitive context and analysis are in the Gosset platform.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCTs051260209.